^
    BIOMARKER:

    KMT2A rearrangement

    i
    Other names: KMT2A, Lysine Methyltransferase 2A, Histone-Lysine N-Methyltransferase 2A, CXXC7, TRX1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila), Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Lysine N-Methyltransferase 2A, Zinc Finger Protein HRX, Trithorax-Like Protein, HTRX1, MLL1A, MLL1, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax (Drosophila) Homolog), Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, Myeloid/Lymphoid Or Mixed
    Entrez ID:
    4297
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    KMT2A rearrangement
    ALL
    CEP-701
    Sensitive: B - Late Trials
    KMT2A rearrangement
    AML
    gemtuzumab ozogamicin
    Sensitive: C3 – Early Trials
    KMT2A rearrangement
    Childhood B Acute Lymphoblastic Leukemia
    blinatumomab
    Sensitive: C3 – Early Trials
    KMT2A rearrangement
    ALL
    azacitidine
    Sensitive: C4 – Case Studies
    KMT2A rearrangement
    Childhood B Acute Lymphoblastic Leukemia
    DS-M1
    Sensitive: D – Preclinical
    KMT2A rearrangement
    ALL
    FLT3 inhibitor + gilteritinib
    Sensitive: D – Preclinical
    KMT2A rearrangement
    ALL
    Menin-MLL inhibitor
    Sensitive: D – Preclinical